Trial Profile

Pilot Study to Determine the Effect of Fractionated Radiotherapy on Expression of Pro-angiogenic Factors in Oesophagus Carcinoma

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 08 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary)
Indications Carcinoma; Oesophageal cancer
Focus Pharmacodynamics; Pharmacogenomic

Most Recent Events

01 Oct 2019 Planned End Date changed from 1 Dec 2017 to 1 May 2021.
01 Oct 2019 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2021.
17 Mar 2017 Planned End Date changed from 1 Apr 2017 to 1 Dec 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com